Q-omics provides the consensus-scored UCHL1 profile across patient tissues and cancer cell-line models. UCHL1 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, UCHL1 is differentially expressed in 14, with the highest sampling consensus in KIRC. Additionally, UCHL1 protein abundance shows 29,697 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRC, and GBM as cancer lineages where UCHL1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for UCHL1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes UCHL1 survival associations across molecular data types. UCHL1 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (2) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible UCHL1 RNA expression–survival associations across cancer types. High UCHL1 expression shows unfavorable associations in KIRC, UVM, MESO, UCEC, BLCA and LIHC. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for UCHL1 RNA expression.
This table summarizes UCHL1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 5. The strongest signals are observed in KIRC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for UCHL1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. UCHL1 shows lower tumor expression in KIRC, COAD and KICH and higher tumor expression in HNSC, LUSC and LUAD. The KIRC box plot shows higher UCHL1 RNA expression in normal versus tumor tissue (log2 FC = −3.299, t-test p < 0.001).
This table shows molecular features associated with UCHL1 in patient tissues and cancer cell lines. In patient samples, UCHL1 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, UCHL1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BLOOD_Lymphoma.
